Vazyme(688105)2024-07-09 10:21Revenue and Profit Projections - The company expects to achieve operating revenue between 640 million and 660 million CNY for the first half of 2024, an increase of 68.96 million to 88.96 million CNY, representing a year-on-year growth of 12.08% to 15.58%[2]. - The net profit attributable to the parent company is projected to be between 15 million and 17 million CNY, marking a turnaround from a loss in the same period last year[2]. - After excluding share-based payment expenses of approximately 38 million CNY, the adjusted net profit is expected to be between 47.35 million and 49.35 million CNY, an increase of 124.71 million to 126.71 million CNY year-on-year[2]. - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is expected to be between -15.5 million and -13.5 million CNY, reflecting a significant narrowing of losses compared to the previous year[2]. - In the same period last year, the company reported an operating revenue of 571.04 million CNY and a net loss of 81.09 million CNY[11]. Business Growth and Management Initiatives - The company has seen rapid growth in its life sciences segment and international business, contributing to steady revenue growth[12]. - The overall expense ratio has significantly improved year-on-year due to ongoing cost reduction and efficiency enhancement measures[12]. - The company has implemented multiple initiatives to strengthen management across procurement, production, and inventory, effectively reducing inventory impairment risks[12]. Forecast Accuracy and Financial Data - The company has not identified any significant uncertainties that could affect the accuracy of this earnings forecast[7]. - The financial data in this earnings forecast has not been audited by a registered accountant and is based on preliminary internal calculations[3].